Genetics and biology of pancreatic ductal adenocarcinoma
Abstract
With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery programs with clearer clinical path hypotheses. A deeper understanding of cancer cell biology, particularly altered cancer cell metabolism and impaired DNA repair processes, is providing novel therapeutic strategies that show strong preclinical activity. Elucidation of tumor biology principles, most notably a deeper understanding of the complexity of immune regulation in the tumor microenvironment, has provided an exciting framework to reawaken the immune system to attack PDAC cancer cells. While the long road of translation lies ahead, the path to meaningful clinical progress has never been clearer to improve PDAC patient survival.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 15, 2016
- Source ID
- 10.1101/gad.275776.115
Entities
People
- Alec C. Kimmelman
- Anirban Maitra
- Giulio F Draetta
- Haoqiang Ying
- Prasenjit Dey
- Ronald A. DePinho
- Wantong Yao
Organizations
- American Association for Cancer Research
- American Cancer Society
- National Institutes of Health
- The University of Texas MD Anderson Cancer Center
- United States Department of Defense
- University of Texas at Austin